About Aristo Biotech
Aristo Biotech is a publicly listed company based in Vadodara (India) founded in 2005. Audio news content is provided to radio stations for broadcast. The company has 53 employees. Its Indian entity Aristo Bio-Tech And Lifescience Limited reported revenue of ₹364 Cr. Aristo Biotech offers products and services including Acetamiprid 20% SP, Glyphosate 41% SL, Hexaconazole 5% EC, Chlormequat Chloride 50% SL, and Cypermethrin 25% EC. Its focus areas include Retail, Contract Manufacturers, Chemicals and Agro Chemicals. Its competitors include Cupid, Inventys and Shogun Organics; 1 of its 3 listed competitors has raised funding.
Company details
Aristo Biotech was established in 2005 in Vadodara, India, within the media sector. Audio news bulletins on politics, business, sports, and international affairs are produced by a team of journalists and distributed through a network to affiliated radio stations. Customized online radio stations are also created for corporate clients, featuring 247 programming, music licensing, and branding integration. Operations focus on content delivery and tailored audio services.
- Headquarters Vadodara, India
- Employees 53
- Stage Public
- SectorsIndustrial Goods & Manufacturing
- Website aristobiotech.com
- Social LinkedIn X Instagram YouTube
- Legal Name Aristo Bio Tech And Lifescience Limited
- Market Cap₹64.33 Cr
ARISTO-SM · NSE
- Share Price₹99.10
+4.87% today
- Revenue₹364 Cr
FY 2025-26 · +14.3% YoY
- EBITDA₹16.05 Cr
Margin 4.4%
- Net Profit₹7.19 Cr
FY 2025-26 · +79.3% YoY
- P/E (TTM)8.5x
P/B 1.4x
- Employee Count53
Associated legal entities of Aristo Biotech
Aristo Biotech operates through Aristo Bio-Tech And Lifescience Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Aristo Bio-Tech And Lifescience Limited Listed CIN L01100GJ2005PLC127397 | Active | 17 Mar 2005 | Vadodara, Gujarat | ₹364 Cr | 53 | 8 | View details |
Products & Services of Aristo Biotech
Aristo Biotech offers a comprehensive portfolio of products and services, including Acetamiprid 20% SP, Glyphosate 41% SL, Hexaconazole 5% EC, Chlormequat Chloride 50% SL, and Cypermethrin 25% EC.
Insecticide for controlling pests on various crops
Herbicide for weed control in agricultural fields
Fungicide to prevent fungal diseases in plants
Regulator to control plant growth and enhance yields
Insecticide for broad-spectrum pest management
Apps and channels of Aristo Biotech
its YouTube channel Aristo Bio-tech And LifeScience Ltd. has 171 subscribers and 2 videos.
Videos from Aristo Biotech
The most watched videos on Aristo Biotech's YouTube channel, Aristo Bio-tech And LifeScience Ltd. (171 subscribers). Click a video to play it here.
More on Aristo Bio-tech And LifeScience Ltd..
Board of directors of Aristo Bio-Tech And Lifescience Limited (Aristo Biotech)
Aristo Bio-Tech And Lifescience Limited is the primary company behind Aristo Biotech. The board of Aristo Bio-Tech And Lifescience Limited currently have 6 directors; the longest-serving is Kusum Narendra Singh Barhat, appointed in 2005. 4 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Kusum Narendra Singh Barhat DIN 00310065 | Director | 17 Mar 2005 | 21 yrs 7 mo | Aristo Bio-Tech And Lifescience Limited |
| Narendra Singh Barhat DIN 00310306 | Managing Director | 17 Mar 2005 | 21 yrs 7 mo | Aristo Bio-Tech And Lifescience Limited |
| Ketankumar Harkantbhai Joshi DIN 02089127 | Whole-time director | 27 Aug 2018 | 8 yrs 2 mo | Aristo Bio-Tech And Lifescience Limited |
| Raghavender Mateti DIN 06826653 | Director | 10 Sep 2018 | 8 yrs 1 mo | Aristo Bio-Tech And Lifescience Limited |
| Laxman Singh Rathore DIN 08218555 | Director | 20 Mar 2022 | 4 yrs 7 mo | Aristo Bio-Tech And Lifescience Limited |
| Rashmi Kamlesh Otavani DIN 06976600 | Director | 20 Mar 2022 | 4 yrs 7 mo | Aristo Bio-Tech And Lifescience Limited |
People of Aristo Biotech
1 people are tracked at Aristo Biotech (1 in leadership); the tracked headcount is 53.
| Name | Role | Group |
|---|---|---|
| Managing Director | Leadership |
Complete people profiles for Aristo Biotech
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Aristo Biotech
Aristo Biotech is a publicly listed company on the NSE with ticker symbol ARISTO in India, operating in the Process industries sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date30 Jan 2023
- Listed onNSE: ARISTO
- Listed entityAristo Bio Tech and Lifescience Limited
- Exchange sectorProcess industries
- ISININE082101010
- Share price₹94.00 · 2026-10-08
- Volume (last session)800
Financials of Aristo Biotech
Exchange-reported figures of Aristo Bio-Tech And Lifescience Limited, the listed company behind Aristo Biotech (NSE: ARISTO-SM).
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 364 | 318 | 245 | 218 | 166 | 167 | 201 |
| Revenue growth | +14.3% | +29.8% | +12.5% | +31.3% | -0.7% | -16.9% | - |
| EBITDA | 16.05 | 9.27 | 8.49 | 8.70 | 5.47 | 4.35 | 4.50 |
| EBITDA margin | +4.4% | +2.9% | +3.5% | +4.0% | +3.3% | +2.6% | +2.2% |
| Profit before tax | 9.70 | 5.46 | 5.41 | 4.74 | 2.05 | 1.50 | 1.39 |
| Net profit | 7.19 | 4.01 | 3.90 | 3.56 | 1.47 | 1.08 | 1.00 |
| Net profit margin | +2.0% | +1.3% | +1.6% | +1.6% | +0.9% | +0.7% | +0.5% |
| EPS (₹) | 10.55 | 5.97 | 5.72 | 5.23 | 2.93 | 2.15 | 2.02 |
| Balance sheet | |||||||
| Total assets | 79.50 | 59.19 | 54.48 | 52.67 | 40.33 | 35.63 | 32.01 |
| Net worth | 44.11 | 37.33 | 33.61 | 30.16 | 14.85 | 13.39 | 12.31 |
| Total debt | 35.40 | 21.85 | 20.87 | 22.49 | 25.48 | 22.25 | 19.71 |
| Cash & bank | 2.63 | 1.12 | 0.64 | 1.85 | 0.42 | 0.11 | 0.53 |
| Net working capital | 54.46 | 34.41 | 32.34 | 35.94 | 25.97 | 23.32 | 20.87 |
| Cash flow | |||||||
| Cash from operations | 8.85 | 10.02 | 7.60 | (2.78) | 6.82 | 2.28 | 1.41 |
| Cash from investing | (2.97) | (5.15) | (6.61) | (3.75) | (3.19) | (1.98) | (2.19) |
| Cash from financing | (4.37) | (4.39) | (2.21) | 7.97 | (3.33) | (0.72) | 0.87 |
Financial Statements
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 364 | 318 | 245 | 218 | 166 | 167 | 201 |
| Revenue growth | +14.3% | +29.8% | +12.5% | +31.3% | -0.7% | -16.9% | - |
| Other income | 0.46 | 0.45 | 0.18 | 0.33 | 0.04 | 0.01 | 0.01 |
| Total expenses | 348 | 309 | 237 | 209 | 161 | 163 | 197 |
| Employee cost | 0.00 | 3.08 | 2.65 | 4.74 | 4.29 | 2.52 | 2.72 |
| EBITDA | 16.05 | 9.27 | 8.49 | 8.70 | 5.47 | 4.35 | 4.50 |
| EBITDA margin | +4.4% | +2.9% | +3.5% | +4.0% | +3.3% | +2.6% | +2.2% |
| Depreciation | 2.92 | 2.60 | 1.57 | 1.54 | 1.10 | 0.75 | 0.52 |
| Interest | 3.89 | 1.66 | 1.69 | 2.75 | 2.36 | 2.11 | 2.60 |
| Profit before tax | 9.70 | 5.46 | 5.41 | 4.74 | 2.05 | 1.50 | 1.39 |
| Tax | 2.51 | 1.40 | 1.51 | 1.18 | 0.57 | 0.42 | 0.39 |
| Net profit | 7.19 | 4.01 | 3.90 | 3.56 | 1.47 | 1.08 | 1.00 |
| Net profit margin | +2.0% | +1.3% | +1.6% | +1.6% | +0.9% | +0.7% | +0.5% |
| EPS (₹) | 10.55 | 5.97 | 5.72 | 5.23 | 2.93 | 2.15 | 2.02 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 6.81 | 6.81 | 6.81 | 6.81 | 5.00 | 5.00 | 5.00 |
| Reserves & surplus | 37.30 | 30.52 | 26.80 | 23.35 | 9.85 | 8.39 | 7.31 |
| Shareholders' funds (net worth) | 44.11 | 37.33 | 33.61 | 30.16 | 14.85 | 13.39 | 12.31 |
| Secured loans | 32.07 | 18.06 | 16.75 | 18.83 | 22.04 | 18.61 | 13.87 |
| Unsecured loans | 3.33 | 3.79 | 4.12 | 3.66 | 3.44 | 3.64 | 5.84 |
| Total debt | 35.40 | 21.85 | 20.87 | 22.49 | 25.48 | 22.25 | 19.71 |
| Total liabilities | 79.50 | 59.19 | 54.48 | 52.67 | 40.33 | 35.63 | 32.01 |
| Assets | |||||||
| Gross block | 37.37 | 34.76 | 30.20 | 22.74 | 19.94 | 16.88 | 12.08 |
| Net block | 23.63 | 23.95 | 21.69 | 15.62 | 14.36 | 12.31 | 8.26 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 1.10 | 0.10 | 0.00 | 2.82 |
| Investments | 0.18 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 63.21 | 47.37 | 40.19 | 30.78 | 24.36 | 31.95 | 24.32 |
| Sundry debtors | 54.73 | 56.18 | 57.47 | 44.57 | 33.20 | 32.77 | 48.31 |
| Cash & bank balances | 2.63 | 1.12 | 0.64 | 1.85 | 0.42 | 0.11 | 0.53 |
| Loans & advances | 9.59 | 11.10 | 6.73 | 5.90 | 4.56 | 4.28 | 3.55 |
| Total current assets | 130 | 116 | 105 | 83.10 | 62.54 | 69.11 | 76.71 |
| Total current liabilities | 75.70 | 81.36 | 72.69 | 47.16 | 36.57 | 45.79 | 55.84 |
| Net working capital | 54.46 | 34.41 | 32.34 | 35.94 | 25.97 | 23.32 | 20.87 |
| Total assets | 79.50 | 59.19 | 54.48 | 52.67 | 40.33 | 35.63 | 32.01 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 1.12 | 0.64 | 1.85 | 0.42 | 0.11 | 0.53 | 0.44 |
| Net cash from operating activities | 8.85 | 10.02 | 7.60 | (2.78) | 6.82 | 2.28 | 1.41 |
| Net cash from investing activities | (2.97) | (5.15) | (6.61) | (3.75) | (3.19) | (1.98) | (2.19) |
| Net cash from financing activities | (4.37) | (4.39) | (2.21) | 7.97 | (3.33) | (0.72) | 0.87 |
| Net change in cash | 1.51 | 0.48 | (1.22) | 1.44 | 0.31 | (0.41) | 0.09 |
| Closing cash | 2.63 | 1.12 | 0.64 | 1.85 | 0.42 | 0.11 | 0.53 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +14.3% | +29.8% | +12.5% | +31.3% | -0.7% | -16.9% | - |
| EBITDA growth | +73.1% | +9.2% | -2.4% | +59.1% | +25.8% | -3.3% | - |
| PBT growth | +77.7% | +0.9% | +14.1% | +131.2% | +36.7% | +7.9% | -66.1% |
| Net income growth | +79.3% | +2.8% | +9.6% | +142.2% | +36.1% | +8.0% | - |
| Revenue CAGR (3Y) | +18.6% | +24.2% | +13.6% | +2.7% | -6.3% | -14.9% | +7.9% |
| EBITDA CAGR (3Y) | +22.7% | +19.2% | +25.0% | +24.6% | -6.8% | -15.9% | +21.0% |
| Profitability & leverage | |||||||
| Net income margin | +2.0% | +1.3% | +1.6% | +1.6% | +0.9% | +0.7% | +0.5% |
| Return on capital employed | - | +12.5% | +13.3% | +16.1% | +11.6% | +10.7% | +13.9% |
| Return on net worth | - | +11.5% | +12.2% | +15.8% | +10.3% | +8.4% | +8.6% |
| Debt / equity | - | 0.60 | 0.68 | 1.07 | 1.69 | 1.63 | 1.45 |
| Long-term debt / equity | - | 0.25 | 0.32 | 0.47 | 0.82 | 0.88 | 0.76 |
| Interest cover | 29.63 | 24.89 | 24.42 | 38.41 | 54.00 | 58.61 | 65.33 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 9.79 | 9.26 | 10.21 | 10.38 | 13.54 | 20.22 |
| Inventory turnover | - | 7.27 | 6.91 | 7.90 | 6.79 | 6.97 | 8.22 |
| Debtors turnover | - | 5.60 | 4.80 | 5.60 | 5.80 | 4.84 | 5.20 |
| EPS (₹) | 10.55 | 5.97 | 5.72 | 5.23 | 2.93 | 2.15 | 2.02 |
| Dividend per share (₹) | 0.60 | 0.50 | 0.40 | 0.25 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 54.84 | 49.37 | 44.30 | 29.71 | 26.79 | 24.63 |
Competitors of Aristo Biotech
Aristo Biotech has 3 listed competitors in our database, 1 of them funded. They include Cupid, Inventys and Shogun Organics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| cupidlimited.com | 1993 | Nashik, India | 224 | Contract manufacturer of male & female condoms | ||
| inventys.in | 2005 | Mumbai, India | $64.34M | 219 | Actives, advanced intermediates, and specialty chemicals are custom manufactured. | |
| shogunorganics.com | 2002 | Mumbai, India | 1,977 | Contract manufacturer of chemicals used in household insecticide products |
Detailed competitors of Aristo Biotech
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Aristo Biotech
The website of Aristo Biotech (aristobiotech.com) receives about 1.6K visits a month.
- Monthly visits1.6K
▼ 17.2% vs previous month
Websites whose visitors overlap most with Aristo Biotech. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
mahindraagri.com | mahindraagri.com | 100% | #2,106,817 | – | |
monsanto.co.za | monsanto.co.za | 75% | – | ||
| growthproducts.com | 75% | View details | |||
| zuari.in | 75% | 6.2K | #3,488,282 | View details | |
news.agropages.com | news.agropages.com | 75% | #2,091,405 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 17 similar websites and full traffic analytics for Aristo Biotech
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 17 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Contract & Outsourced Manufacturing
3 companies that operate in the same segment as Aristo Biotech (Contract & Outsourced Manufacturing) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Industrial components, mould bases, and storage solutions are manufactured globally. | 1986 | Coimbatore, Tamil Nadu, India | USD 28 M | USD 853.09 M | 43 | |
Single- and three-phase transformers are manufactured in Mumbai. | 1993 | Mumbai, Maharashtra, India | USD 114.37 M | 618 | ||
Apparel and clothing are manufactured and exported on contract. | 1979 | Bengaluru, Karnataka, India | USD 400 M | 40,280 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aristo Biotech
Complete news archive for Aristo Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aristo Biotech
Aristo Biotech was founded in 2005.
Aristo Biotech is headquartered in Vadodara, India. It is registered at Vadodara, Gujarat, India.
Aristo Biotech has 53 employees.
The primary company behind Aristo Biotech, Aristo Bio-Tech And Lifescience Limited, reported revenue of ₹364 Cr for FY 2026, up 14% year on year.
Aristo Biotech was established in 2005 in Vadodara, India, within the media sector. Audio news bulletins on politics, business, sports, and international affairs are produced by a team of journalists and distributed through a network to affiliated radio stations. Customized online radio stations are also created for corporate clients, featuring 247 programming, music licensing, and branding integration. Operations focus on content delivery and tailored audio services.
Aristo Biotech's top competitors include Inventys, Shogun Organics and Cupid.
Aristo Biotech offers Acetamiprid 20% SP, Glyphosate 41% SL, Hexaconazole 5% EC, Chlormequat Chloride 50% SL, and Cypermethrin 25% EC.
Yes, Aristo Biotech is publicly traded on NSE under the ticker symbol ARISTO.
Aristo Biotech operates through Aristo Bio-Tech And Lifescience Limited.
The legal entities of Aristo Biotech currently have 7 directors, including Raghavender Mateti, Laxman Singh Rathore, Kusum Narendra Singh Barhat and others.